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Abstract: Glulisine (Apidra®) is a rapid-acting human insulin analog approved for use in 
children with diabetes mellitus $4 years of age. Management of children with type 1 diabetes 
has seen a shift in favor of mimicking normal physiological insulin responses with multiple 
daily injections or continuous subcutaneous insulin infusions (CSII). Few studies have com-
pared the rapid-acting insulin analogs in this population but limited data indicate that glulisine 
is as effective as lispro when used in a basal–bolus regimen. This review appraises the current 
available studies and reviews on insulin glulisine in children. An extensive keyword search of 
‘insulin glulisine’, ‘insulin analogs’, and ‘Apidra’ in the pediatric population was performed. 
These studies have suggested that glulisine is safe, well tolerated, and is an effective option in 
the diabetes armamentarium. Further studies are needed to determine its safety for use in CSII 
pumps in the pediatric population.
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Introduction
Type 1 diabetes mellitus is one of the most common chronic diseases in children in 
the developed world. The incidence in children is growing at 3% to 5% per year1 and 
the risk of hypoglycemia has always been a limiting factor in attempts to achieve 
near-normoglycemia. In recent years, particularly because of improved insulins and 
insulin delivery devices, it has been possible to lower blood glucose levels more easily 
with a reduced risk of hypoglycemia, thus decreasing the chances of microvascular, 
macrovascular, and neuropathic damage (ie, diabetes complications) in the future. 
The Diabetes Control and Complications Trial (DCCT)2 and its follow-up study, 
Epidemiology of Diabetes Interventions and Complications (EDIC),3 highlighted 
that a reduction in glycosylated hemoglobin (HbA1c), even when it remains above the 
recommended target goal, has a beneficial impact on long-term prognosis, the now 
recognized ‘metabolic memory effect’, important in minimizing microvascular and 
macrovascular complications.2–4
Metabolic memory is based on the concept that initial poor glycemic control during 
the diabetes disease course is associated with an increased risk of diabetes complica-
tions, despite optimal glycemic control later in the disease course (and vice versa). This 
emphasizes the desirability of attaining and maintaining excellent glycemic control 
from the time of diagnosis. However, in children and adolescents with type 1 diabetes, 
this may be difficult to obtain as a result of the need to balance multiple daily insulin 
injections with variations in dietary and exercise patterns.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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The approach to diabetes management is complex, and 
hypoglycemia arising from attempts to achieve normogly-
cemia (or near-normoglycemia) is understandably feared by 
children, parents, and clinicians. Despite this, in recent years, 
there has been a shift in the approach to managing children 
with newly diagnosed type 1 diabetes, in order to optimize 
their glycemic control. This has been aided by the avail-
ability and accepted use of insulin analogs, insulin pens, and 
  continuous subcutaneous insulin infusions (CSII) pumps.
Insulin analogs were first available for clinical use in 
1996, a major advantage being reduced hypoglycemic 
episodes compared with regular human insulin (RHI; 
Figure 1).5,6 In adults, changing treatment from RHI to 
insulin analogs generally results in a reduction of HbA1c 
levels, but a similar change has not been documented in 
children. Glulisine is one of the newest insulin analogs and 
is approved for use in children $4 years of age (and aged 
$ 6 years in Europe).7,8
An extensive review of the literature utilizing PubMed, 
EMBASE, Cochrane Collaboration, and Ovid Medline did 
not reveal clinical trials favoring superiority of glulisine 
above other insulin analogs. In this review, clinical trials that 
included ‘glulisine’ as a key word in the pediatric population 
were included (open and blinded, randomized, nonrandom-
ized, crossover designs), regardless of dose or schedule. The 
participants of these studies were aged 4 to 17 years of age of 
either sex. All participants had confirmatory type 1 diabetes. 
The main outcome data in the efficacy studies were changes 
in HbA1c at study completion. To date, efficacy data on type 
2 diabetes in the pediatric population have not been studied, 
but several trials have been performed in adults.9–11
Additional searching was made by cross referencing origi-
nal articles and reviews. Abstracts were screened from major 
meetings and the abstract included in this review was sourced 
from Diabetologica. Enquiries were made to sanofi-aventis on 
future research, there are two ongoing Phase IV clinical trials 
currently in progress, the results of which are yet to be pub-
lished. These trials have not yet completed recruitment.12
This review will describe the pharmacokinetic and phar-
macodynamic studies, available in children. The efficacy 
trials will focus on comparison of glulisine with insulin 
lispro. The safety concerns and quality of life issues will be 
discussed based on the available trials in children.
Glulisine
Structure
Glulisine (Apidra®; sanofi-aventis, Paris, France) is a rapid-
acting recombinant insulin analog which differs from RHI 
by the substitution of lysine for asparagine at position B3 
and glutamic acid for lysine at position B29.13
The chemical name of insulin glulisine is 3B-Lys-29B-
Glu-human insulin.14
Glulisine is the newest addition to the class of rapid-acting 
recombinant insulin analogs. Lispro is created by substituting 
proline for lysine at position B28 and lysine for proline at 
position B29, effectively reversing the amino acids sequence 
at positions 28 and 29 of the insulin beta-chain (Figure 3). 
Aspart is homologous to RHI except for the substitution of 
proline for aspartic acid at B28 (Figure 4).
Monomers, dimmers, and hexamers
In solution, insulin molecules exist in equilibrium between 
monomers, dimers, tetramers, hexamers, and higher-order 
aggregates. Human insulin is best absorbed in its monomeric 
form but, at physiologic pH, normal insulin molecules tend 
to associate into dimers and subsequently hexamers in the 
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presence of zinc. Consequently, the absorption of RHI is 
limited by the degree and strength of self association of 
insulin molecules.15
The amino acid substitutions of glulisine and other rapid-
acting insulin analogs promote monomer stability, allowing 
for rapid dissociation and absorption after subcutaneous 
injection. In addition, the isolectric point (pI) is lowered 
to 5.1, enhancing solubility at physiological pH.16
The dimer and hexameric forms of human insulin confer 
conformational stability and are less likely to denature in stor-
age.17 In aspart and lispro, zinc is added in order to stabilize the 
molecules in hexamers to achieve a practical shelf-life.18,19
Unlike the other rapid-acting insulin analogs, the oligo-
meric molecules of glulisine are stable without the addition 
of zinc, presumably because of the unaltered proline at 
position B28 thus allowing dimerization.20 Polysorbate 20, a 
surfactant, is added to the product composition to prevent the 
irreversible formation of aggregates (fibrils) from monomers, 
further enhancing physical stability.17
Mechanism of action
Insulin and its analogs lower serum glucose levels by 
facilitating glucose uptake in skeletal muscle and fat, and 
by inhibiting gluconeogenesis, glycogenolysis, lipolysis, 
and proteolysis through its effect on the insulin receptor. 
Compared with RHI, there are no differences in association, 
dissociation, or receptor binding affinity.21
Pharmacokinetics 
and pharmacodynamics
There have been limited studies in children evaluating phar-
macokinetics and pharmacodynamics of glulisine. A double-
blind, randomized, crossover study of 20 pediatric patients 
incorporated a single-dose (0.15 U/kg) of either glulisine 
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Figure 2 Aspart insulin.
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or RHI administered 2 minutes before a weight-adjusted 
standardized liquid meal. Patients were stratified into two 
groups of 10 patients each: children (aged 5 to 11 years) and 
adolescents (aged 12 to 17 years).22 Comparable to adults 
with type 1 diabetes, glulisine in children and adolescents 
afforded a greater early insulin exposure as assessed by 
  (INS-AUC0–1h) (insulin concentration [area under curve]) 
and INS-AUC0–2h, while overall concentrations of insulin as 
assessed by   INS-AUC0–6h were comparable. Glulisine reached 
a higher maximum concentration (Cmax 58 µIU/L vs 33 µIU/L; 
P , 0.05) compared with RHI and achieved this in shorter 
period of time (tmax 54 minutes vs 66 minutes) (see Table 1). 
The median residence time was shorter at 88 minutes com-
pared with 137 minutes for RHI (P , 0.05).
Pharmacokinetic profiles for glulisine given to children 
and adolescents were almost equivalent, as demonstrated 
by point estimates close to 100%. In contrast, adolescents 
administered RHI demonstrated a 62% higher early exposure 
to insulin (INS-AUC0–2h), 64% higher overall concentrations 
of insulin (INS-AUC0–6h), and a 76% higher insulin Cmax 
compared with children (see Table 2).
Total glucose exposure (BG-AUC), maximum blood 
glucose concentration (BGmax), and maximum glucose excur-
sion from baseline (∆BGmax) were also significantly lower in 
pediatric patients administered glulisine compared to RHI 
(P , 0.05). The trend persisted when children and adoles-
cents were analyzed separately (see Table 3).
There are currently no pharmacokinetic studies compar-
ing glulisine with lispro or aspart.
Efficacy
An Ovid Medline search of the published literature found 
a limited number of articles on the use of glulisine among 
pediatric patients. There was one published pharmacokinetic 
study,22 three review articles,23,24 and a recent abstract25 
detailing the safety and efficacy of lispro versus glulisine. 
Although the data are limited, the literature is in favor of 
the general efficacy of glulisine as a rapid-acting analog in 
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Figure 4 Glulisine insulin.
Table 1 Pharmacokinetics of glulisine (GLU) versus regular human insulin (RHi)
GLU (geometric mean) RHI (geometric mean) GLU/RHI point 
estimate (95% CI)
iNS-AUC0–1h (µiU⋅min-1⋅mL-1) 2287 1246 176% (127, 244)
iNS-AUC0–2h (µiU⋅min-1⋅mL-1) 5232 2994 169% (127, 224)
iNS-AUC0–4h (µiU⋅min-1⋅mL-1) 7624 5703 130% (99, 170)
iNS-AUC0–6h (µiU⋅min-1⋅mL-1) 8361 7052 116% (90, 150)
Cmax (µiU⋅mL-1) 58 33 171% (127, 229)
tmax (min) 54a 66† -8 min (-24, 7)
MRT (min) 88 137 64% (59, 70)
Note: aMedian. Copyright © 2005, American Diabetes Association. Adapted with permission from Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, 
prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005;28(9):2100–2105.
Abbreviations: CI, confidence limits; INS-AUC (µiU⋅min-1⋅mL-1), insulin concentration (area under curve); Cmax (µiU⋅mL-1), maximum insulin concentration; tmax (min), time 
to Cmax; MRT (min), median residence time.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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pediatric patients. There are insufficient data to support its 
efficacy and safety via CSII.26,27
Glulisine versus lispro
A 26-week, multicenter, centrally randomized noninferi-
ority trial compared the efficacy of glulisine with lispro 
in 572 children (aged 4 to 17 years) with type 1 diabetes 
treated with basal insulin (either glargine once daily or NPH 
twice daily).25 Most patients had 3 to 4 bolus injections 
(58% of those on glulisine, 60.5% of those on lispro) and 
blood glucose control remained stable throughout the study 
period. Baseline-to-endpoint HbA1c changes were similar 
in both groups (glulisine lispro -0.06%, 95% confidence 
interval -0.24 to 0.12; prespecified noninferiority margin 
0.4%). However, the percentage of patients achieving 
  American Diabetes Association (ADA) age-specific HbA1c 
targets at endpoint was significantly higher with glulisine 
(38.4%) than with lispro (32%) (P = 0.0386). This dif-
ference was particularly pronounced in adolescents (13 to 
17 years), 31.1% of glulisine-treated subjects versus 21.1% 
of lispro-treated subjects achieving the age-specific HbA1c 
target of ,7.5% at endpoint (P = 0.0251).
Based on these findings, Philotheou et al25 concluded that 
glulisine is noninferior to lispro in the long-term reduction 
of HbA1c in pediatric patients with type I diabetes.
Several well designed trials have studied glulisine (with 
and without basal insulin) with comparator insulin analogs 
in adults. In adults with type 1 diabetes the efficacy has been 
investigated in three randomized, active-controlled, noninfe-
riority studies.28–30 Two of these studies evaluated glulisine 
Table 2 Pharmacokinetics of glulisine (GLU) and regular human insulin (RHi) in children versus adolescents
Children
GLU 
(geometric mean)
Children
RHI 
(geometric mean)
Adolescents
GLU
(geometric mean)
Adolescents
RHI
(geometric mean)
GLU
point estimate
(95% CI)
RHI
point estimate
(95% CI)
iNS-AUC0–1h 
(µiU⋅min-1⋅mL-1)
2170 1023 2410 1552 111% 
(70, 175)
152% 
(89, 258)
iNS-AUC0–2h 
(µiU⋅min-1⋅mL-1)
4948 2383 5534 3860 112% 
(72, 174)
162% (105, 250)
iNS-AUC0–4h 
(µiU⋅min-1⋅mL-1)
7193 4530 8081 7367 112% 
(72, 175)
163% (111, 238)
iNS-AUC0–6h 
(µiU⋅min-1⋅mL-1)
7934 5581 8811 9145 111% 
(73, 169)
164% (114, 236)
Cmax (µiU⋅mL-1) 55 25 61 44 112% 
(73, 172)
177% (112, 281)
tmax (min) 55a 59a 52† 76a -2 minb 
(–9, 11)
9 minb 
(–24, 49)
MRT (min) 87 132 90 144 103% 
(88, 121)
110% 
(92, 130)
Notes: aMedian; bPoint estimates (95% Ci) for the respective median differences from nonparametric data analysis. Copyright © 2005, American Diabetes Association. 
Adapted with permission from Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children 
and adolescents with type 1 diabetes. Diabetes Care. 2005;28(9):2100–2105.
Abbreviations: CI, confidence limits; INS AUC (µiU⋅min-1⋅mL-1), insulin concentration (area under curve); Cmax (µiU⋅mL-1), maximum insulin concentration; tmax (min), time 
to Cmax; MRT (min), median residence time.
Table 3 Postprandial glucose glulisine (GLU) versus regular human insulin (RHi)
Glulisine (Geometric mean) RHI (Geometric mean) GLU/RHI
point estimate 
(95% confidence limits)
BG-AUC0–1h (mg⋅h-1⋅dL-1) 57 29 73% (59, 90)
BG-AUC0–2h (mg⋅h-1⋅dL-1) 179 263 68% (56, 82)
BG-AUC0–4h (mg⋅h-1⋅dL-1) 419 627 67% (55, 80)
BG-AUC0–6h (mg⋅h-1⋅dL-1) 641 801 80% (67, 95)
BGmax (mg/dL) 298 352 85% (77, 93)
∆BGmax (mg/dL) 166 224 74% (64, 86)
BGmin (mg/dL) 211 193 109% (93, 128)
Notes: Copyright © 2005, American Diabetes Association. Adapted with permission from Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, 
prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005;28(9):2100–2105.
Abbreviations: BG AUC, blood glucose (area under curve); ∆BGmax, maximum baseline subtracted blood glucose concentration; BGmax, maximum glucose excursion from 
baseline; BGmin, minimum blood glucose concentrations.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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with insulin lispro.29,30 The primary endpoint in these   studies 
were changes in HbA1c from baseline to study endpoint. 
The baseline characteristics of these adult type 1 diabetes 
participants were similar between the two groups (glulisine 
vs lispro). Glulisine in both studies was noninferior to lispro 
and the increase in basal insulin (glargine) dose in glulisine 
recipients was lower than in the lispro group.
Glulisine versus aspart
There were no trials comparing the efficacy of glulisine with 
aspart in pediatric patients.
Glulisine and CSii
Glulisine has not been approved by the Food Drug Administra-
tion for use in children or adults via CSII, but two clinical26,27 
and two in vitro studies have investigated its use.
One study, performed in adult patients, was a 12-week 
multicenter, randomized trial that compared the efficacy and 
safety of glulisine versus aspart used in CSII in 59 patients 
with type I diabetes.26 The median catheter occlusion rate, 
overall rate of catheter change, and frequency of infusion 
site reactions were similar for both insulin forms. Each treat-
ment group showed a slight increase in mean HbA1c over 
the 12 weeks (0.2% increase for glulisine, 0.1% increase 
for aspart).
The second clinical study, which included adolescents and 
adults, was a crossover trial looking at timing of meal-  related 
glulisine bolus administration via CSII in 23   subjects.27 
A bolus of glulisine 20 minutes prior to a meal was found 
to result in significantly better postprandial glucose control 
than glulisine administration immediately prior to the meal 
or 20 minutes after meal initiation.
An important property of insulin products in CSII is 
their ability to remain soluble and resist precipitation when 
exposed to various environments. Although the longest 
  duration clinical study using CSII with glulisine did not 
show any increase in catheter occlusion rates compared 
with aspart,19 in vitro studies suggest glulisine could theo-
retically be more liable to precipitate. One study, utilizing 
reverse-phase high performance liquid chromatography to 
assess resistance to isoelectric precipitation of various types 
of insulin,16 found that the resistance was highest for aspart 
and lowest for glulisine, but the clinical significance of this 
is unclear. A second in vitro study assessed the stability of 
glulisine and aspart during simulated use in insulin pumps 
(flow rates 0.3 U/hour and 0.9 U/hour).30 Although both 
forms of insulin initially retained high proportions of native 
insulin, at day 10 glulisine contained double the amount of 
high-molecular-weight proteins, which are less biologically 
potent than the native molecule and may potentially be 
immunogenic. Glulisine has also been shown to be more 
prone than aspart to form insoluble insulin fibrils, which 
are not biologically potent. On the basis of these studies, it 
is clear that further studies will be required before glulisine 
can be approved for use in CSII.
Phase iv ongoing clinical trials
There are two Phase IV ongoing trials with glulisine in chil-
dren and adolescents with type 1 diabetes.12 Both trials are 
currently recruiting patients, and both are proposed to be com-
pleted in 2010. To date no data are available (see Table 4).
Safety
Studies suggest that glulisine has a similar safety profile to 
the other new rapid-acting insulin analogs and that it is well 
tolerated.1,21,22,25,26,32,33
Hypoglycemia
The most common adverse event with glulisine, as with all 
insulins is hypoglycemia.32 However, hypoglycemia does not 
Table 4 Ongoing phase 4 studies of glulisine in children and adolescents
Investigator Year of study Age Inclusion criteria Study design and aim
Cemeroglua 2009–2010 4–11 years Prepubertal (tanner stage i)
Type 1 diabetes mellitus with positive islet 
cell antibodies or presenting at time of 
diagnosis with positive serum or urine 
ketones and requiring insulin since diagnosis 
HbA1c 6.9%–10% 
Crossover study:
The effect of glulisine and aspart on breakfast 
postprandial blood glucose levels in prepubertal 
children with type 1 diabetes mellitus on multiple 
daily insulin injection therapy
Phillipb 2009–2010 7–20 years Type 1 diabetes diagnosed ,12 months prior 
to study entry
HbA1c $ 8.0
A randomized, crossover, open study in order to 
compare treatment satisfaction with glargine plus 
glulisine vs NPH insulin plus glulisine in newly 
diagnosed children and adolescents with type 1 
diabetes 
Notes: aClinical trials gov identifier NCT00913497, Principal Investigator A. Cemiroglu; bClinical Trials gov identifier NCT00925977, Principal Investigator M. Phillip.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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appear to be any more frequent or severe with glulisine than 
with other rapid-acting insulin analogs.
Philotheou et al25 conducted a 26-week multicenter open 
centrally randomized, parallel group, noninferiority trial of 
572 children and adolescents, aged 4 to 17 years with type 
1 diabetes using glargine once daily in the evening or NPH 
twice daily as basal insulin and glulisine or lispro as the bolus 
insulin. Despite a significantly higher percentage of patients 
on glulisine achieving ADA age-specific HbA1c targets at 
endpoint (38.4% vs 32% in the lispro group; P = 0.0386) 
and total and severe symptomatic hypoglycemic rates were 
similar between the two groups from the fourth month to the 
endpoint. There were 3.10 hypoglycemic events per patient 
per month for the glulisine group versus 2.91 for the lispro 
group while, for severe symptomatic hypoglycemia, there 
were 0.06 events per patient per month in the glulisine group 
and 0.07 in the lispro group.
A small crossover trial of 10 children and 10 adolescent 
patients with type 1 diabetes comparing RHI and glulisine 
found no severe hypoglycemic events.22
There are no trials of glulisine use in CSII in a purely 
pediatric population, but in a study in 59 adults with type 1 
diabetes comparing glulisine with aspart a similar frequency 
of hypoglycemia was found between the two groups.26
Hypersensitivity and insulin  
injection site reactions
In children no generalized hypersensitivity reactions have been 
reported, although there are few studies in this population.
In a pooled analysis of 1833 patients receiving glulisine 
versus comparator short-acting insulin in 1524 patients, both 
groups had a 4% incidence of potential systemic allergic 
reactions.32 In a 26-week study of 672 adults with type 1 
diabetes.14 Dreyer et al found that systemic hypersensitivity 
reactions occurred in 1.8% of the glulisine group and 1.2% 
of the lispro group. Insulin injection site reactions occurred 
in 3% of patients on glulisine and 4% of those on lispro.14
When glulisine was compared with aspart in CSII in 59 
adult patients with type 1 diabetes the frequency of infusion-
site reactions was similar between the two groups.26
Cancer risk
There is no evidence that glulisine or any of the other 
rapid-acting insulin analogs cause increased mitogenesis, 
potentially leading to cancer, compared with RHI. There is a 
theoretical concern that they could increase the risk of tumor 
development due to altered binding characteristics to insulin 
and insulin-like growth factor (IGF)-1 receptors caused by 
the structural changes made to the native insulin molecule. 
However, preclinical studies suggest that structural changes 
in glulisine compared with RHI are not associated with any 
risk of tumorigenesis.21,33
Stammberger showed that steady state insulin receptor 
binding affinity was slightly lower for glulisine than for RHI 
(∼0.70) and that glulisine has a 4- to 5-fold lower affinity 
for IGF-1 receptor binding than RHI.33 Glulisine and RHI 
showed similar insulin receptor-association kinetics and insu-
lin receptor-mediated phosphorylation and insulin receptor 
substrate (IRS)-2 activation. Activation of IRS-1 was 6- to 
10-fold lower with glulisine. Stimulation of DNA synthesis 
was comparable for glulisine and RHI in K6 myoblasts and 
there was no difference in proliferative activity between the 
two insulins at 12 months.
In another study, glulisine demonstrated the same asso-
ciation, dissociation- and insulin-receptor affinity kinetics 
as RHI.21
Other adverse effects
When glulisine was compared with RHI in a small crossover 
trial in 10 adolescents and 10 children with type 1 diabetes, 
no safety concerns arose.1 Nineteen mild adverse events were 
reported in nine patients. Other than urticaria in a patient 
on RHI, details of the adverse reactions were not provided. 
There were no severe hypoglycemic events or clinically rel-
evant abnormalities on physical examinations or in pathology 
tests.
When glulisine was compared with aspart in 59 adults with 
type 1 diabetes on CSII, unexplained hyperglycemia occurred 
in fewer patients in the glulisine group (20% vs 40%).26
Lipodystrophy and weight gain
Lipodystrophy and weight gain can each occur in adult sub-
jects on long-term glulisine therapy.32 However, the pediatric 
trials do not report data relating to these effects.
Catheter occlusion in CSii pumps
Although there are theoretical concerns that glulisine could be 
associated with an increase in catheter occlusion in CSII,16,27 
the one study comparing glulisine with aspart in pumps did 
not show a significant difference in catheter occlusion, and 
rates for both were low.26
Tolerability
Flexibility of administration
In general, use of rapid-acting insulin analogs gives greater 
flexibility for the timing of injections, especially important Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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for children and teenagers. Insulin administration can be 
given immediately prior to or immediately after a meal, 
with the dose being adjusted according to carbohydrate 
intake, blood glucose level, and physical activity. The 
potential to give glulisine immediately after a meal, 
once food intake is known, can be invaluable in young 
children in whom carbohydrate and other food intake can 
vary widely and be difficult to predict.34 A comparable 
degree of glycemic control has been shown if glulisine 
is administered immediately prior to or 15 minutes after 
a meal.35
Patient satisfaction
There are no data relating to treatment satisfaction in 
patients on glulisine versus RHI. However, a number of 
studies, mainly in adults, have shown higher satisfaction in 
subjects on lispro or aspart compared with RHI.36,37 Adults 
randomized to aspart instead of RHI in an open label trial 
reported increased satisfaction, mainly due to increased 
meal and leisure time flexibility.38 As the pharmacody-
namics and efficacy of glulisine are very similar to those 
of these other rapid-acting insulin analogs, it is likely that 
treatment satisfaction on glulisine will also be higher than 
for patients on RHI.
Quality of life
No specific studies have addressed quality of life (QoL) in 
patients on glulisine.
However, QoL was higher in children, adolescents, 
and adults transferred from RHI to lispro.38–41 and was also 
improved in the majority of Japanese children (78%) with 
type 1 diabetes treated with rapid-acting insulin analogs, 
either aspart or lispro, compared with RHI.42 Since aspart, lis-
pro, and glulisine have similar pharmacodynamics, it is likely 
that glulisine will also have a beneficial effect on QoL.
Discussion
Several large trials have studied glulisine in adult patients 
with type 1 and type 2 diabetes, but data in the pediatric 
population are limited. Glulisine compares favorably with 
other rapid-acting insulin analogs in the treatment of chil-
dren with type 1 diabetes, but there is no evidence that it 
has superior safety or efficacy. However, it has been shown 
to be noninferior to lispro in terms of efficacy and safety as 
part of a basal-bolus regimen in pediatric patients with type 
1 diabetes.25 It is thus a safe and effective short-acting insulin 
option in this population.
The pharmacokinetic and pharmacodynamic properties 
of glulisine appear to be similar in pediatric and adult 
patients. Glulisine has a similar kinetic profile to lispro and 
has a more rapid onset and shorter duration of action than 
RHI.22 These properties of rapid-acting insulin analogs are 
particularly advantageous in children, as they allow insulin 
administration postprandially or a short time preprandi-
ally with similar glycemic control. This is useful in young 
children, in whom it may be difficult to accurately predict 
carbohydrate intake.34 The shorter duration of action allows 
more flexibility of insulin dosing with variable activity 
levels.
There are no documented safety concerns with insulin 
glulisine use in children in a subcutaneous basal-bolus 
regimen. Rates of hypoglyemia are similar to rates with 
other rapid-acting analogs. Insulin injection-site reac-
tions and systemic reactions are low and similar to those 
of other rapid-acting insulin analogs. In vitro studies do 
not suggest any increase in the risk of mitogenesis with 
glulisine.
There are still insufficient data to recommend routine 
use of glulisine in CSII in children, particularly in view 
of the possible concerns about catheter occlusion and 
insulin injection-site reactions. Despite this, while there 
are no published studies assessing the safety of glulisine 
administered via CSII in this population, a study compar-
ing glulisine with aspart via CSII in adults revealed no 
adverse reactions.26
From the few published studies relating to glulisine in 
the pediatric population, it appears to provide a safe and 
effective option as a rapid-acting insulin analog as part of a 
basal-bolus regimen in children $4 years of age with type 1 
diabetes.7,8,32 Its use will be based on a combination of factors 
including clinician–patient preference, ease of administration 
(such as the use of the disposable SoloSTAR pen; sanofi-
aventis), and convenience with immediately pre- or postmeal 
injections. Comparative studies with the other rapid-acting 
insulin analogs are needed before the place of glulisine in the 
management of children and adolescents with type 1 diabetes 
can be better defined.
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